Companies ›Healthcare ›COCH.O

COCH.O — NASDAQ Advanced Medical Equipment & Technology

Envoy Medical Inc

$0,69

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

53,1M USD

P/E

—

EV / Rev

—

Div yield

—

Op margin

-9 240,7 %

ROE

195,4 %

Net margin

-9 857,3 %

Debt / equity

0,00

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$0,68

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Envoy Medical Inc is a healthcare equipment and technology company that develops and commercializes medical devices, primarily focused on the urology and women's health markets.

Business. Envoy Medical Inc (COCH.O) is a healthcare services and equipment company operating in the advanced medical equipment and technology industry. The firm generates revenue through the sale of products, with key performance indicators including organic revenue growth, procedure volume, and gross margin. Envoy Medical is listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic mix are not available.

Classification99 %

SectorHealth Care

Industry groupAdvanced Medical Equipment & Technology

Generated · model-assisted

Sell-side consensus

BUY1 analysts

1 buy0 hold0 sell

Avg 12m price target2,50

Analyst recommendations

1 analysts · consensus Buy

Buy1

Hold0

Sell0

12-month price target

2,50

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

1 analysts · indicative

Ownership→

Geode Capital Management, L.L.C.

largest disclosed fund holder

Profitability→

195,4 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning COCH.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to COCH.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

Briefing · model-assisted

Envoy Medical Inc (COCH.O) has recorded a new institutional holding, marking a notable shift in its investor base. As of March 31, 2026, an investor identified by ID 931 added a position of 5.0 shares, valued at approximately $0.000003 million. This acquisition represents a weight of roughly 1.44e-09% of the total portfolio for that specific holder, signaling initial interest from the institutional community. This development is particularly significant as it constitutes the first analysis for this ticker, meaning there is no prior basis for computing delta changes in holdings or financial metrics. The absence of previous data points makes this new entry a foundational reference for tracking future investor sentiment and capital flows into the company. From a broader company perspective, Envoy Medical currently reports zero officers and zero analyst coverage, alongside no index memberships. The presence of 11 top holders, including the newly added investor, suggests a concentrated ownership structure despite the lack of broader market visibility or professional analyst attention. The addition of this holder, detected on June 20, 2026, serves as an early indicator of potential institutional engagement. While the share count and value are minimal, the act of establishing a position in a company with no prior analyst coverage or index inclusion may reflect niche interest or early-stage accumulation strategies by specific investors.

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Envoy Medical Inc (COCH.O) is a healthcare services and equipment company operating in the advanced medical equipment and technology industry. The firm generates revenue through the sale of products, with key performance indicators including organic revenue growth, procedure volume, and gross margin. Envoy Medical is listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic mix are not available.

Classification99 %

SectorHealth Care

Industry groupAdvanced Medical Equipment & Technology

AI synthesis

GENERATED

Envoy Medical Inc operates with a negative equity position of $12.16 million and a total asset base of $8.56 million, indicating a highly leveraged and capital-intensive structure. The company's liquidity position is weak, with a current ratio of 0.54, suggesting limited ability to meet short-term obligations. The company's market capitalization of $50.74 million is significantly lower than its total liabilities of $20.72 million, indicating a high degree of financial leverage and potential insolvency risk.

The company's profitability metrics are deeply negative, with a net loss of $23.76 million and an operating loss of $22.27 million in the latest reporting period. Its return on equity of 1.95 is misleading due to the negative equity base, and its return on assets of -2.78% indicates that the company is not generating returns from its asset base. These figures are well below the industry median for profitability and returns, suggesting a company in distress relative to its peers.

Envoy Medical Inc's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financial data. This lack of diversification increases the company's exposure to market-specific risks and limits its ability to offset losses in one area with gains in another. The company's revenue of $241.00 million is modest in scale, and there is no indication of significant growth in recent periods.

The company's growth trajectory is uncertain, with no disclosed revenue growth in the latest financial data. Analysts have assigned a mean price target of $6.00, which is significantly higher than the current market price of $0.66, suggesting some optimism about the company's future potential. However, the absence of positive earnings and the company's negative cash flow position raise questions about the sustainability of any near-term growth.

The company's risk profile is elevated, with a low liquidity rating and a negative equity position. The absence of long-term debt is a positive factor, but the company's operating cash flow of -$18.20 million and free cash flow of -$30.36 million indicate a significant cash burn rate. The risk assessment indicates no immediate filing-based liquidity or dilution flags, but the company's financial position suggests a high risk of further dilution or restructuring.

Recent events and filings do not indicate any material changes in the company's financial or operational status. The company has not disclosed any significant new product launches, partnerships, or strategic initiatives in the latest reporting period. The absence of capital expenditures beyond $179,000 suggests limited investment in growth or innovation.

Key takeaways

Envoy Medical Inc is operating with a negative equity position and a weak liquidity profile, indicating a high risk of insolvency.
The company's profitability metrics are deeply negative, with a net loss of $23.76 million and an operating loss of $22.27 million.
Revenue is concentrated in a single business segment, with no geographic diversification disclosed, increasing exposure to market-specific risks.
Analysts have assigned a mean price target of $6.00, significantly higher than the current market price, but the company's financial position raises questions about the sustainability of any near-term growth.
The company's risk profile is elevated, with a low liquidity rating and a negative equity position, suggesting a high risk of further dilution or restructuring.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$0,69

Market cap

$50.7M

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

-$12.2M

Net cashⓘ

—

Current ratioⓘ

0.5

Debt / equityⓘ

0.0

ROAⓘ

-2.8%

ROEⓘ

2.0%

Cash conversionⓘ

77.0%

CapEx / revenueⓘ

-74.3%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs COCH · multiples and returns

TMO—

Thermo Fisher Scientific Inc

$574,03

214,1B USD

P/E

29,4x

— vs self

Div yield

0,3 %

— vs self

ROE

12,9 %

+246,7 vs self

DHR—

Danaher Corp

$197,50

140,1B USD

P/E

38,2x

— vs self

Div yield

—

— vs self

ROE

6,9 %

+240,7 vs self

GEHC—

GE HEALTHCARE TECHNOLOGIES INC.

$69,72

31,9B USD

P/E

13,6x

— vs self

Div yield

0,2 %

— vs self

ROE

19,5 %

+253,3 vs self

PHG—

PHG

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

BSX—

Boston Scientific Corp

$48,54

72,6B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

ISRG—

INTUITIVE SURGICAL, INC.

$376,00

133,2B USD

P/E

287,7x

— vs self

Div yield

—

— vs self

ROE

3,6 %

+237,4 vs self

A—

Agilent Technologies Inc

$139,80

39,6B USD

P/E

29,0x

— vs self

Div yield

0,8 %

— vs self

ROE

19,3 %

+253,1 vs self

EW—

Edwards Lifesciences Corp

$88,82

51,6B USD

P/E

44,3x

— vs self

Div yield

—

— vs self

ROE

10,4 %

+244,2 vs self

Market position

Stress test

— missing data

Predictor forecast

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-0,29
Revenue	—no estimate	—no estimate	219,000 USD
Operating income	—no estimate	—no estimate	-21,5M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Corporate eventM&A horizon

M&A probabilityconf 5 %

Probability

5 %

Base rate

3 %

Band

—

180-day horizon · target 2027-01-16 · 1,8× base rate

No acquirer candidates identified by the signal model.

Probabilistic model output — not investment advice. · generated 2026-07-20

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution1 analysts

Strong buy0

Buy1

Hold0

Sell0

Strong sell0

12-month price target$2,50 · Median $2,50

Low $2,50High $2,50

Operating income · consensus-21,5M USD

Revenue surprise

+10,0 %

reported vs consensus · beat

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$2,50

Mean$2,50

Median$2,50

High$2,50

Spot$0,69

+262.1 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

Op Margin-9 240,7 %Bottom quartile

Net Margin-9 857,3 %Bottom quartile

ROE195,4 %Best in class

Capex / Rev-74,3 %Bottom quartile

D/E0,00Above median

Cash Conv0,77Below median

Corporate actions / M&A

M&A probabilityconf —

Probability

5 %

Base rate

3 %

Band

Moderate

180-day horizon · target 2027-01-16 · 1,8× base rate

No acquirer candidates identified by the signal model.

Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 35 208 840 sh13 grants9 insiders

Lucas Brent T.Director, Chief Executive Officer · Stock Option (right to buy) → Class A Common StockAcquired 1 000 000 @ $0,63grant · 2026-06-19
Lucas Brent T.Director, Chief Executive Officer · Restricted Stock Units → Class A Common StockAcquired 1 000 000grant · 2026-06-19
McKhann ChasDirector · Stock Option (Right to Buy) → Class A Common StockAcquired 100 000 @ $0,72grant · 2026-04-15
Patel Mona ChetanDirector · Warrant (right to buy) → Class A Common StockAcquired 187 500 @ $0,40purchase · 2026-02-12
Potashnick RobertInterim CFO · Warrant (right to buy) → Class A Common StockAcquired 212 500 @ $0,40purchase · 2026-02-12
Potashnick RobertInterim CFO · Warrant (right to buy) → Class A Common StockAcquired 127 500 @ $0,40purchase · 2026-02-12
Patel Mona ChetanDirector · Warrant (right to buy) → Class A Common StockAcquired 312 500 @ $0,40purchase · 2026-02-12
Kantor SusanDirector · Warrant (right to buy) → Class A Common StockAcquired 96 150 @ $0,40purchase · 2026-02-12
Lucas Brent T.Director, Chief Executive Officer · Warrant (right to buy) → Class A Common StockAcquired 62 500 @ $0,40purchase · 2026-02-12
Kantor SusanDirector · Warrant (right to buy) → Class A Common StockAcquired 57 690 @ $0,40purchase · 2026-02-12
TAYLOR GLEN A10% owner · Warrant Shares (Series A-1) → Class A Common StockAcquired 11 250 000 @ $0,40purchase · 2026-02-12
Lucas Brent T.Director, Chief Executive Officer · Warrant (right to buy) → Class A Common StockAcquired 37 500 @ $0,40purchase · 2026-02-12
TAYLOR GLEN A10% owner · Warrant Shares (Series A-2) → Class A Common StockAcquired 18 750 000 @ $0,40purchase · 2026-02-12
BRYNELSEN CHARLESDirector · Warrant (right to buy) → Class A Common StockAcquired 1 000 000 @ $0,40purchase · 2026-02-12
BRYNELSEN CHARLESDirector · Warrant (right to buy) → Class A Common StockAcquired 600 000 @ $0,40purchase · 2026-02-12
Lucas Brent T.Director, Chief Executive Officer · Stock Option (right to buy) → Class A Common StockAcquired 200 000 @ $0,53grant · 2026-02-05
Potashnick RobertInterim CFO · Stock Option (right to buy) → Class A Common StockAcquired 15 000 @ $0,53grant · 2026-02-05
Kantor SusanDirector · Stock Option (right to buy) → Class A Common StockAcquired 62 500 @ $0,81grant · 2025-12-03
Smith-Gomez JanisDirector · Stock Option (right to buy) → Class A Common StockAcquired 25 000 @ $0,81grant · 2025-12-03
Crowe Michael CurtisDirector · Stock Option (right to buy) → Class A Common StockAcquired 25 000 @ $0,81grant · 2025-12-03
Patel Mona ChetanDirector · Stock Option (right to buy) → Class A Common StockAcquired 25 000 @ $0,81grant · 2025-12-03
BRYNELSEN CHARLESDirector · Stock Option (right to buy) → Class A Common StockAcquired 62 500 @ $0,81grant · 2025-12-03
TAYLOR GLEN ADirector, 10% owner · Warrant (right to buy) → Class A Common StockDisposed 500 000 @ $1,24disposition · 2025-09-04
TAYLOR GLEN ADirector, 10% owner · Warrant (right to buy) → Class A Common StockAcquired 750 000 @ $1,35grant · 2025-09-04
TAYLOR GLEN ADirector, 10% owner · Warrant (right to buy) → Class A Common StockDisposed 750 000 @ $1,35disposition · 2025-09-04

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity

Source documents

Envoy Medical Inc Market data — financials · 2026-05-27
Envoy Medical Inc Market data — analyst estimates · 2026-05-27

Ownership & reference

Top holders

Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$0M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$0M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$0M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$0M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$0M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M

Insider activity

Net buying6 buys · 0 sellsnet $8,2M6 insiders · last 365d

Lucas Brent T.Director, Chief Executive Officer · Class A Common StockOther 32 856 @ $0,60$20K · 2026-05-29
Patel Mona ChetanDirector · Class A Common StockBought 312 500 @ $0,40$125K · 2026-02-12
Potashnick RobertInterim CFO · Class A Common StockBought 212 500 @ $0,40$85K · 2026-02-12
Kantor SusanDirector · Class A Common StockBought 96 150 @ $0,40$38K · 2026-02-12
BRYNELSEN CHARLESDirector · Class A Common StockBought 1 000 000 @ $0,40$400K · 2026-02-12
Lucas Brent T.Director, Chief Executive Officer · Class A Common StockBought 62 500 @ $0,40$25K · 2026-02-12
TAYLOR GLEN A10% owner · Class A Common StockBought 18 750 000 @ $0,40$7,5M · 2026-02-12
Lucas Brent T.Director, Chief Executive Officer · Class A Common StockOther 18 105 @ $0,71$13K · 2025-11-28

Short positioning

879.9Kshares short-10.6% vs prior

2.25days to cover

45.4%short of daily vol

4fails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

COCH.OCanonical

NASDAQ · USD

Intel & risk

PredictorM&A prob5 %Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Evidence & claims

From filings & derived data

EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 17.4%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -33.1%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): -25.8%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 35.5%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): 7.1%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): 22.7%Derived (calculated)
Debt-to-equity (FY 2025-12-31): -1.67xDerived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): -15.7%Derived (calculated)
Current ratio (FY 2025-12-31): 0.54xDerived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -1.4%Derived (calculated)
Net margin (FY 2025-12-31): -9,857.3%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): -14.2%Derived (calculated)
Return on assets (FY 2025-12-31): -277.6%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 17.4%Derived (calculated)
Return on equity (FY 2025-12-31): 195.4%Derived (calculated)
Capex (YoY) (2025-12-31 vs 2024-12-31): -81.7%Derived (calculated)
Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 17.8%Derived (calculated)
R&D expense (annual): USD 12.49MSEC XBRL filing
Cost of revenue (annual): USD 874KSEC XBRL filing
EPS (basic) (annual): USD-PER-SHARES -1SEC XBRL filing
Operating income (annual): USD -22.27MSEC XBRL filing
Current assets (annual): USD 6.28MSEC XBRL filing
Operating cash flow (annual): USD -18.2MSEC XBRL filing
Current liabilities (annual): USD 11.56MSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-07-30 00:00 UTCTRANSCRIPTEarnings call — Q3 2026

2026-07-30EVENTQ2 2026 earnings (expected) estimated date

2026-07-29 22:34 UTCEVENTHa Price Listing COCH remains DEFICIENT (NASDAQ) — cure period. closed below $1.00 for 171 consecutive trading days (last close $0.6418). cure deadline 2027-01-17 (172 days remaining).

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)

2026-06-21 02:57 UTCHOLDERInstitutional holding changed

2026-06-21 02:57 UTCHOLDER1 institutional position change flagged

2026-06-19 00:00 UTCINSIDER2 insider transactions — 2026-06 2 derivative

2026-06-19INSIDERLucas Brent T. acquired 1.00M sh Restricted Stock Units — Director, Chief Executive Officer

2026-05-29 00:00 UTCINSIDER1 insider transaction — 2026-05

2026-05-29INSIDERLucas Brent T. transacted 32.9k sh Class A Common Stock — Director, Chief Executive Officer ~$20k

2026-05-22FILINGCURRENT REPORT →

2026-05-18FILINGCURRENT REPORT →

2026-05-11FILINGQUARTERLY REPORT →

2026-05-11FILINGCURRENT REPORT →

2026-04-21FILINGCURRENT REPORT →

2026-04-15 00:00 UTCINSIDER1 insider transaction — 2026-04 1 derivative

2026-04-15INSIDERMcKhann Chas acquired 100.0k sh Stock Option (Right to Buy) — Director

2026-04-02FILINGPROXY STATEMENT →

2026-03-31FILINGCURRENT REPORT →

2026-03-27FILINGCURRENT REPORT →

2026-03-23FILINGANNUAL REPORT →

2026-02-27FILINGCURRENT REPORT →

2026-02-13FILINGCURRENT REPORT →

2026-02-12 00:00 UTCINSIDER20 insider transactions — 2026-02 · net buy $8.2M 14 derivative

2026-02-12FILINGPROSPECTUS →

2026-02-12INSIDERPatel Mona Chetan bought 312.5k sh Class A Common Stock — Director ~$125k

2026-02-12INSIDERPotashnick Robert bought 212.5k sh Class A Common Stock — Interim CFO ~$85k

2026-02-12INSIDERKantor Susan bought 96.2k sh Class A Common Stock — Director ~$38k

2026-02-12INSIDERBRYNELSEN CHARLES bought 1.00M sh Class A Common Stock — Director ~$400k

2026-02-12INSIDERLucas Brent T. bought 62.5k sh Class A Common Stock — Director, Chief Executive Officer ~$25k

2026-02-12INSIDERTAYLOR GLEN A bought 18.75M sh Class A Common Stock — 10% owner ~$7.50M

2026-02-12INSIDERPatel Mona Chetan acquired 312.5k sh Warrant (right to buy) — Director

2026-02-12INSIDERPotashnick Robert acquired 212.5k sh Warrant (right to buy) — Interim CFO

2026-02-12INSIDERPatel Mona Chetan acquired 187.5k sh Warrant (right to buy) — Director

2026-02-12INSIDERPotashnick Robert acquired 127.5k sh Warrant (right to buy) — Interim CFO

Showing the 40 most recent of 59 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread